Bladder-Pain Patients Taking Elmiron Should See An Ophthalmologist For Vision Loss Testing

Doctors should advise Elmiron (pentosan polysulfate sodium) patients to undergo ophthalmic screening for those that pose vision complaints

Wednesday, April 7, 2021 - Doctors that treat patients that have Interstitial Cystitis (IC), better known as painful bladder syndrome, and have prescribed Elmiron, have a dilemma to face now that the drug has come under pressure for allegedly causing vision damage. Scientists are concluding that Elmiron potentially causes maculopathy and macular degeneration. What is more alarming is that the vision damage may not end when a patient stops taking the drug. Researchers believe that trouble seeing in sub-optimal lighting conditions will continue and may worsen even if one discontinues taking the bladder pain medicine. Also, the longer one has taken Elmiron, the greater the reported alleged vision damage. Other alarming facts about Elmiron that have emerged from studies is that an estimated 33% of all Elmiron patients may develop some degree of vision loss, and about 20% of the millions of Elmiron patients could develop some degree of blindness. Even more astonishing is that Elmiron may benefit only 1 out of 3 patients and is no more effective than a placebo. Doctors that regularly prescribe Elmiron should advise their patients of the terrible possibility that they could lose their vision. Elmiron researchers writing in the National Institute of Health have concluded, "We recommend disclosing the emergence of this potential toxicity to exposed patients. We further suggest ophthalmic screening in any PPS-exposed patient with any vision complaints about evidence of this maculopathy." Elmiron Eyesight lawsuits are handled by national attorneys with experience litigating against big pharmaceutical companies.

Elmiron-induced maculopathy is an insidious condition that affects a patient so gradually that many think their vision loss is due to their progressing age. Doctors have labeled the disease age-related macular degeneration, however, there is good reason to believe it could be called Elmiron-related macular degeneration. Maculopathy is best described by DrugWatch as "... a progressive disease that can lead to vision loss, usually in both eyes. The disease affects a part of the eye in the back of the retina called the macula. The macula controls the ability to read, see fine detail in objects, recognize faces and colors and focus central vision." Other side effects of Elmiron (pentosan polysulfate sodium) may be as damaging to one's overall health as the vision damage the drug allegedly causes. WebMD warns that Elmiron can cause "diarrhea, hair loss, nausea, headache, stomach upset, or abdominal."

Since September 26, 1996, Janssen Pharmaceuticals, a subsidiary of the Johnson & Johnson medical group, has enjoyed a monopoly selling Elmiron as the only FDA-approved drug to treat Interstitial cystitis/bladder pain syndrome (IC/BPS). Elmiron patients have experienced forms of night blindness and trouble seeing while in sub-optimal lighting conditions and blame the drug. Many are speaking with Elmiron Blindness lawyers to see if they qualify to file a claim to seek monetary compensation. If your vision has been affected after having taken Elmiron you should not be intimidated by the legal resources of large, multinational companies like Johnson & Johnson.

More Recent Elmiron Eye Lawsuit News:

Lawyers for Elmiron Eye Lawsuits

Attorneys handling Elmiron Eye lawsuits for leukemia, non-Hodgkin lymphoma, and multiple myeloma offer free, no-obligation case review for individuals and families who believe they may have grounds to file a Elmiron Eye lawsuit. Working on a contingency basis, these attorneys are committed to never charging legal fees unless they win compensation in your Elmiron Eye lawsuit. The product liability litigators handling Roundup claims at OnderLaw have a strong track record of success in representing families harmed by dangerous drugs and consumer products.